Related references
Note: Only part of the references are listed.Gut microbiome, liver immunology, and liver diseases
Rui Wang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis
Cathrin L. C. Gudd et al.
JOURNAL OF HEPATOLOGY (2021)
FAECAL MICROBIOTA TRANSPLANT FOR REFRACTORY CHECKPOINT INHIBITOR IMMUNOTHERAPY-RELATED COLITIS
Vincent Cheung et al.
GUT (2021)
VEDOLIZUMAB FOR INFLAMMATORY BOWEL DISEASE IN PRE AND POST LIVER TRANSPLANT
Yooyun Chung et al.
GUT (2021)
Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis
Weihua Chen et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2020)
Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
Kate D. Lynch et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
MAIT Cells in Health and Disease
Nicholas M. Provine et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 38 (2020)
Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis
Masanori Furukawa et al.
HEPATOLOGY RESEARCH (2020)
Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors
Mar Riveiro-Barciela et al.
LIVER INTERNATIONAL (2020)
Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the east Midlands UK - a retrospective observational study
Jonathan R. White et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2020)
Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk
Agostino Di Ciaula et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Characterization of gut-homing molecules in non-endstage livers of patients with primary sclerosing cholangitis and inflammatory bowel disease
Manon de Krijger et al.
JOURNAL OF TRANSLATIONAL AUTOIMMUNITY (2020)
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease
Silvio Danese et al.
GASTROENTEROLOGY (2019)
FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis
Marcel Sorribas et al.
JOURNAL OF HEPATOLOGY (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development
Juliette Mouries et al.
JOURNAL OF HEPATOLOGY (2019)
Bidirectional Cross-Talk between Biliary Epithelium and Th17 Cells Promotes Local Th17 Expansion and Bile Duct Proliferation in Biliary Liver Diseases
Hannah C. Jeffery et al.
JOURNAL OF IMMUNOLOGY (2019)
Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases
Maryam Tahvildari et al.
JOURNAL OF IMMUNOLOGY (2019)
The association between antibiotics in the first year of life and child growth trajectory
Elizabeth E. Dawson-Hahn et al.
BMC PEDIATRICS (2019)
Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial
Jessica R. Allegretti et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)
Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy
Ruqi Tang et al.
GUT (2018)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease
B. Christensen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease
C. S. Tse et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
The impact of ileal pouch-anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis
P. J. Trivedi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Mo1845 - Higher Serum Concentrations of Vedolizumab are Associated with Superior Endoscopic Outcomes in Crohn's Disease: Data from the Love-CD Trial
Sophie E. Berends et al.
GASTROENTEROLOGY (2018)
Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents
Daniel L. Suzman et al.
LIVER INTERNATIONAL (2018)
Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease
Kazumichi Abe et al.
PLOS ONE (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis
Guillaume Pineton de Chambrun et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2018)
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort
S. Tadbiri et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis
Vincenzo Ronca et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease
Eva Kristine Klemsdal Henriksen et al.
JOURNAL OF HEPATOLOGY (2017)
Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids
Aafke W. F. Janssen et al.
JOURNAL OF LIPID RESEARCH (2017)
Current and emerging therapeutic targets for IBD
Markus F. Neurath
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Association Between Breast Milk Bacterial Communities and Establishment and Development of the Infant Gut Microbiome
Pia S. Pannaraj et al.
JAMA PEDIATRICS (2017)
Bile Acid Physiology
Agostino Di Ciaula et al.
ANNALS OF HEPATOLOGY (2017)
Homeostasis of the gut barrier and potential biomarkers
Jerry M. Wells et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2017)
Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis
James H. Tabibian et al.
HEPATOLOGY (2016)
The enteric microbiome in hepatobiliary health and disease
James H. Tabibian et al.
LIVER INTERNATIONAL (2016)
Mechanisms of Pediatric Inflammatory Bowel Disease
Joanna M. Peloquin et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
Immunological functions of liver sinusoidal endothelial cells
Percy A. Knolle et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2016)
Reversing T-cell Dysfunction and Exhaustion in Cancer
Hassane M. Zarour
CLINICAL CANCER RESEARCH (2016)
The Gut-Liver Axis in Primary Sclerosing Cholangitis
Bertus Eksteen
CLINICS IN LIVER DISEASE (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity
Palak J. Trivedi et al.
JOURNAL OF AUTOIMMUNITY (2016)
A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study
Shahab Rahimpour et al.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES (2016)
Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1
Hannah C. Jeffery et al.
JOURNAL OF HEPATOLOGY (2016)
Primary Sclerosing Cholangitis
Konstantinos N. Lazaridis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Human Intestinal Microbiome in Health and Disease
Susan V. Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
New Therapeutic Strategies for Primary Sclerosing Cholangitis
Kate D. Williamson et al.
SEMINARS IN LIVER DISEASE (2016)
Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives
Hannah C. Jeffery et al.
FRONTIERS IN IMMUNOLOGY (2016)
Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab
Saqib Mumtaz et al.
FRONTLINE GASTROENTEROLOGY (2016)
Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab
Jill M. V. Petkau et al.
BIOLOGICS-TARGETS & THERAPY (2016)
Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life
Fredrik Backhed et al.
CELL HOST & MICROBE (2015)
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Colleen R. Kelly et al.
GASTROENTEROLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Antibiotic Exposure in Infancy and Risk of Being Overweight in the First 24 Months of Life
Antti Saari et al.
PEDIATRICS (2015)
A gut-vascular barrier controls the systemic dissemination of bacteria
Ilaria Spadoni et al.
SCIENCE (2015)
Microbiota Modulation of Myeloid Cells in Cancer Therapy
Romina S. Goldszmid et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma A Pooled Analysis of 4 Clinical Trials
James Larkin et al.
JAMA ONCOLOGY (2015)
Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease
Lauren N. Cherry et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2015)
The gut microbiota keeps enteric glial cells on the move; prospective roles of the gut epithelium and immune system
Panagiotis S. Kabouridis et al.
GUT MICROBES (2015)
Review article: anti-adhesion therapies for inflammatory bowel disease
T. Lobaton et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Vascular Cell Adhesion Molecule 1 Expression by Biliary Epithelium Promotes Persistence of Inflammation by Inhibiting Effector T-Cell Apoptosis
Simon C. Afford et al.
HEPATOLOGY (2014)
Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics
Rachel N. Carmody et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity
Anne Vrieze et al.
JOURNAL OF HEPATOLOGY (2014)
The Liver May Act as a Firewall Mediating Mutualism Between the Host and Its Gut Commensal Microbiota
Maria L. Balmer et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Secondary bile acids: an underrecognized cause of colon cancer
Hana Ajouz et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2014)
Designing biologic selectivity for inflammatory bowel disease - role of vedolizumab
Niklas Krupka et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2014)
Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study
J. H. Tabibian et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
The TGR5 gene is expressed in human subcutaneous adipose tissue and is associated with obesity,Weight loss and resting metabolic rate
Per-Arne Svensson et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Role of gut microbiota in liver diseases
Yasuhiro Miyake et al.
HEPATOLOGY RESEARCH (2013)
Immunomodulatory Effect of Vancomycin on Treg in Pediatric Inflammatory Bowel Disease and Primary Sclerosing Cholangitis
David N. Abarbanel et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2013)
Therapeutic strategies in inflammasome mediated diseases of the liver
Rafaz Hoque et al.
JOURNAL OF HEPATOLOGY (2013)
Lipopolysaccharide Clearance, Bacterial Clearance, and Systemic Inflammatory Responses Are Regulated by Cell Type-Specific Functions of TLR4 during Sepsis
Meihong Deng et al.
JOURNAL OF IMMUNOLOGY (2013)
Primary sclerosing cholangitis
Gideon M. Hirschfield et al.
LANCET (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cells
Lucy J. Walker et al.
BLOOD (2012)
Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut
Ekihiro Seki et al.
JOURNAL OF PHYSIOLOGY-LONDON (2012)
Antibiotics in early life alter the murine colonic microbiome and adiposity
Ilseung Cho et al.
NATURE (2012)
MR1 presents microbial vitamin B metabolites to MAIT cells
Lars Kjer-Nielsen et al.
NATURE (2012)
Human gut microbiome viewed across age and geography
Tanya Yatsunenko et al.
NATURE (2012)
The gut microbiota and its relationship to diet and obesity New insights
Siobhan F. Clarke et al.
GUT MICROBES (2012)
Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity
Janne Prawitt et al.
DIABETES (2011)
Regulation of Mucosal Addressin Cell Adhesion Molecule 1 Expression in Human and Mice by Vascular Adhesion Protein 1 Amine Oxidase Activity
Evaggelia Liaskou et al.
HEPATOLOGY (2011)
The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation
Thijs W. H. Pols et al.
JOURNAL OF HEPATOLOGY (2011)
Human nutrition, the gut microbiome and the immune system
Andrew L. Kau et al.
NATURE (2011)
Genetics and pathogenesis of inflammatory bowel disease
Bernard Khor et al.
NATURE (2011)
Enterotypes of the human gut microbiome
Manimozhiyan Arumugam et al.
NATURE (2011)
Altered biliary epithelial cell and monocyte responses to lipopolysaccharide as a TLR ligand in patients with primary biliary cirrhosis
Jingmin Zhao et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2011)
FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
Serkan Kir et al.
SCIENCE (2011)
Bile Acids as Regulators of Hepatic Lipid and Glucose Metabolism
Michael Trauner et al.
DIGESTIVE DISEASES (2010)
Long-term bacterial exposure can trigger nonsuppurative destructive cholangitis associated with multifocal epithelial inflammation
Ikuko Haruta et al.
LABORATORY INVESTIGATION (2010)
High Expression of the Bile Salt-Homeostatic Hormone Fibroblast Growth Factor 19 in the Liver of Patients with Extrahepatic Cholestasis
Frank G. Schaap et al.
HEPATOLOGY (2009)
Hepatic Regulatory T Cells and Kupffer Cells Are Crucial Mediators of Systemic T Cell Tolerance to Antigens Targeting Murine Liver
Ekaterina Breous et al.
HEPATOLOGY (2009)
Epidemiology of Idiosyncratic Drug-Induced Liver Injury
Lauren N. Bell et al.
SEMINARS IN LIVER DISEASE (2009)
The Natural History of Drug-Induced Liver Injury
Einar Bjornsson
SEMINARS IN LIVER DISEASE (2009)
Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders
Stefano Fiorucci et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
CCL25 and CCL28 promote α4β7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow
Alice Miles et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2008)
Mechanism of T cell tolerance induction by murine hepatic Kupffer cells
Qiang You et al.
HEPATOLOGY (2008)
Clinical features and management of primary sclerosing cholangitis
Marina G. Silveira et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease
Oscar Pastor Rojo et al.
INFLAMMATORY BOWEL DISEASES (2007)
Genetic polymorphisms associated with inflammatory bowel disease do not confer risk for primary sclerosing cholangitis
Tom H. Karlsen et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Bile salt hydrolase activity in probiotics
M Begley et al.
APPLIED AND ENVIRONMENTAL MICROBIOLOGY (2006)
Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease
DH Adams et al.
NATURE REVIEWS IMMUNOLOGY (2006)
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
EV Loftus et al.
GUT (2005)
Retinoic acid imprints gut-homing specificity on T cells
M Iwata et al.
IMMUNITY (2004)
Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis
B Eksteen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Regulated production of the chemokine CCL28 in human colon epithelium
H Ogawa et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2004)
Comparison among fecal secondary bile acid levels, fecal microbiota and Clostridium scindens cell numbers in Japanese
M Kitahara et al.
MICROBIOLOGY AND IMMUNOLOGY (2004)
Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells
JR Mora et al.
NATURE (2003)
Bile acids induce the expression of the human peroxisome proliferator-activated receptor α gene via activation of the farnesoid X receptor
IP Torra et al.
MOLECULAR ENDOCRINOLOGY (2003)
MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease)
AJ Grant et al.
HEPATOLOGY (2001)
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis
CJ Sinal et al.
CELL (2000)
Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity
EJ Kunkel et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
